Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches
The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and t...
- Autores:
-
Navarro, Carla
Ortega, Ángel
Santeliz, Raquel
Garrido, Bermary
Chacín, Maricarmen
Galban, Néstor
Vera, Ivana
Bautista de Sanctis, Juan
Bermúdez, Valmore
- Tipo de recurso:
- Fecha de publicación:
- 2022
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- eng
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/11380
- Acceso en línea:
- https://hdl.handle.net/20.500.12442/11380
https://doi.org/10.3390/pharmaceutics14061303
- Palabra clave:
- Metabolic reprogramming
tumor microenvironment
energy metabolism
neoplasms
carbohydrates
inflammation
Immunotherapy
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivatives 4.0 Internacional
id |
USIMONBOL2_7938c433237a5c638d82f2543e3f7c93 |
---|---|
oai_identifier_str |
oai:bonga.unisimon.edu.co:20.500.12442/11380 |
network_acronym_str |
USIMONBOL2 |
network_name_str |
Repositorio Digital USB |
repository_id_str |
|
dc.title.eng.fl_str_mv |
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
title |
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
spellingShingle |
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches Metabolic reprogramming tumor microenvironment energy metabolism neoplasms carbohydrates inflammation Immunotherapy |
title_short |
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
title_full |
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
title_fullStr |
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
title_full_unstemmed |
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
title_sort |
Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches |
dc.creator.fl_str_mv |
Navarro, Carla Ortega, Ángel Santeliz, Raquel Garrido, Bermary Chacín, Maricarmen Galban, Néstor Vera, Ivana Bautista de Sanctis, Juan Bermúdez, Valmore |
dc.contributor.author.none.fl_str_mv |
Navarro, Carla Ortega, Ángel Santeliz, Raquel Garrido, Bermary Chacín, Maricarmen Galban, Néstor Vera, Ivana Bautista de Sanctis, Juan Bermúdez, Valmore |
dc.subject.eng.fl_str_mv |
Metabolic reprogramming tumor microenvironment energy metabolism neoplasms carbohydrates inflammation Immunotherapy |
topic |
Metabolic reprogramming tumor microenvironment energy metabolism neoplasms carbohydrates inflammation Immunotherapy |
description |
The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and tumor development in addition to cell heterogeneity. Consequently, this hallmark promotes resistance to conventional anti-tumor therapies by adapting to the drastic changes in the nutrient microenvironment that these therapies entail. Therefore, it represents a revolutionary landscape during cancer progression that could be useful for developing new and improved therapeutic strategies targeting alterations in cancer cell metabolism, such as the deregulated mTOR and PI3K pathways. Understanding the complex interactions of the underlying mechanisms of metabolic reprogramming during cancer initiation and progression is an active study field. Recently, novel approaches are being used to effectively battle and eliminate malignant cells. These include biguanides, mTOR inhibitors, glutaminase inhibition, and ion channels as drug targets. This review aims to provide a general overview of metabolic reprogramming, summarise recent progress in this field, and emphasize its use as an effective therapeutic target against cancer. |
publishDate |
2022 |
dc.date.accessioned.none.fl_str_mv |
2022-11-17T20:13:19Z |
dc.date.available.none.fl_str_mv |
2022-11-17T20:13:19Z |
dc.date.issued.none.fl_str_mv |
2022 |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.driver.eng.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.spa.spa.fl_str_mv |
Artículo científico |
dc.identifier.citation.eng.fl_str_mv |
Navarro, C., Ortega, Á., Santeliz, R., Garrido, B., Chacín, M., Galban, N., Vera, I., De Sanctis, J. B., & Bermúdez, V. (2022). Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches. Pharmaceutics, 14(6), 1303. https://doi.org/10.3390/pharmaceutics14061303 |
dc.identifier.issn.none.fl_str_mv |
19994923 |
dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12442/11380 |
dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.3390/pharmaceutics14061303 |
identifier_str_mv |
Navarro, C., Ortega, Á., Santeliz, R., Garrido, B., Chacín, M., Galban, N., Vera, I., De Sanctis, J. B., & Bermúdez, V. (2022). Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches. Pharmaceutics, 14(6), 1303. https://doi.org/10.3390/pharmaceutics14061303 19994923 |
url |
https://hdl.handle.net/20.500.12442/11380 https://doi.org/10.3390/pharmaceutics14061303 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.rights.*.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.rights.accessrights.eng.fl_str_mv |
info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 Internacional http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2 |
eu_rights_str_mv |
openAccess |
dc.format.mimetype.spa.fl_str_mv |
pdf |
dc.publisher.spa.fl_str_mv |
MDPI |
dc.source.eng.fl_str_mv |
Pharmaceutics Vol. 14 Issue 6 (2022) |
institution |
Universidad Simón Bolívar |
bitstream.url.fl_str_mv |
https://bonga.unisimon.edu.co/bitstreams/391a7bbf-9d3c-44dd-a633-3beac1f5e973/download https://bonga.unisimon.edu.co/bitstreams/4c677b1a-6966-40db-898e-d6136cbcc665/download https://bonga.unisimon.edu.co/bitstreams/38077a90-8da0-43a0-bc76-27f30012ca7a/download https://bonga.unisimon.edu.co/bitstreams/173c1cde-b713-4357-846b-19b6dbf90b21/download https://bonga.unisimon.edu.co/bitstreams/7bbc93f0-617c-4427-974f-22884a309ff8/download https://bonga.unisimon.edu.co/bitstreams/258de599-098f-4650-8891-17490d9dc36e/download https://bonga.unisimon.edu.co/bitstreams/42ff302a-dcfa-403e-9b4f-7d841730d488/download |
bitstream.checksum.fl_str_mv |
4460e5956bc1d1639be9ae6146a50347 733bec43a0bf5ade4d97db708e29b185 51390448584b1fb3ebd39467f380e874 e7701454589dcf88ba2f64a588ca3e8a e7701454589dcf88ba2f64a588ca3e8a 9d6ffd30d3874017fc01a5d2fd9c3304 9d6ffd30d3874017fc01a5d2fd9c3304 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Digital Universidad Simón Bolívar |
repository.mail.fl_str_mv |
repositorio.digital@unisimon.edu.co |
_version_ |
1814076145100914688 |
spelling |
Navarro, Carla9892bf34-10a9-479a-8b3a-6769d4804207Ortega, Ángelb6a809bb-4d26-4e53-9419-e4eb9fb40a9bSanteliz, Raquel5e2f7a44-1208-4164-83cb-743abf6a557dGarrido, Bermary5bac9928-0ee3-4e86-9c28-f6b1bff624e9Chacín, Maricarmen5c3b3d7c-4444-47e2-b2be-11f08df10409Galban, Néstordce44827-2bbc-421d-a1dd-15201c3cf3c5Vera, Ivana89ef899e-d9fb-4348-b1ff-f1b3543f4019Bautista de Sanctis, Juanf8cc21e7-74e9-457d-b895-4cde4c75afe4Bermúdez, Valmore29f9aa18-16a4-4fd3-8ce5-ed94a0b8663a2022-11-17T20:13:19Z2022-11-17T20:13:19Z2022Navarro, C., Ortega, Á., Santeliz, R., Garrido, B., Chacín, M., Galban, N., Vera, I., De Sanctis, J. B., & Bermúdez, V. (2022). Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches. Pharmaceutics, 14(6), 1303. https://doi.org/10.3390/pharmaceutics1406130319994923https://hdl.handle.net/20.500.12442/11380https://doi.org/10.3390/pharmaceutics14061303The constant changes in cancer cell bioenergetics are widely known as metabolic reprogramming. Reprogramming is a process mediated by multiple factors, including oncogenes, growth factors, hypoxia-induced factors, and the loss of suppressor gene function, which support malignant transformation and tumor development in addition to cell heterogeneity. Consequently, this hallmark promotes resistance to conventional anti-tumor therapies by adapting to the drastic changes in the nutrient microenvironment that these therapies entail. Therefore, it represents a revolutionary landscape during cancer progression that could be useful for developing new and improved therapeutic strategies targeting alterations in cancer cell metabolism, such as the deregulated mTOR and PI3K pathways. Understanding the complex interactions of the underlying mechanisms of metabolic reprogramming during cancer initiation and progression is an active study field. Recently, novel approaches are being used to effectively battle and eliminate malignant cells. These include biguanides, mTOR inhibitors, glutaminase inhibition, and ion channels as drug targets. This review aims to provide a general overview of metabolic reprogramming, summarise recent progress in this field, and emphasize its use as an effective therapeutic target against cancer.pdfengMDPIAttribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2PharmaceuticsVol. 14 Issue 6 (2022)Metabolic reprogrammingtumor microenvironmentenergy metabolismneoplasmscarbohydratesinflammationImmunotherapyMetabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approachesinfo:eu-repo/semantics/articleArtículo científicohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_2df8fbb1CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://bonga.unisimon.edu.co/bitstreams/391a7bbf-9d3c-44dd-a633-3beac1f5e973/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8381https://bonga.unisimon.edu.co/bitstreams/4c677b1a-6966-40db-898e-d6136cbcc665/download733bec43a0bf5ade4d97db708e29b185MD53ORIGINALPDF.pdfPDF.pdfPDFapplication/pdf2685327https://bonga.unisimon.edu.co/bitstreams/38077a90-8da0-43a0-bc76-27f30012ca7a/download51390448584b1fb3ebd39467f380e874MD51TEXT2022_MDPI_Metabolic Reprogramming.pdf.txt2022_MDPI_Metabolic Reprogramming.pdf.txtExtracted texttext/plain100265https://bonga.unisimon.edu.co/bitstreams/173c1cde-b713-4357-846b-19b6dbf90b21/downloade7701454589dcf88ba2f64a588ca3e8aMD54PDF.pdf.txtPDF.pdf.txtExtracted texttext/plain100265https://bonga.unisimon.edu.co/bitstreams/7bbc93f0-617c-4427-974f-22884a309ff8/downloade7701454589dcf88ba2f64a588ca3e8aMD56THUMBNAIL2022_MDPI_Metabolic Reprogramming.pdf.jpg2022_MDPI_Metabolic Reprogramming.pdf.jpgGenerated Thumbnailimage/jpeg5700https://bonga.unisimon.edu.co/bitstreams/258de599-098f-4650-8891-17490d9dc36e/download9d6ffd30d3874017fc01a5d2fd9c3304MD55PDF.pdf.jpgPDF.pdf.jpgGenerated Thumbnailimage/jpeg5700https://bonga.unisimon.edu.co/bitstreams/42ff302a-dcfa-403e-9b4f-7d841730d488/download9d6ffd30d3874017fc01a5d2fd9c3304MD5720.500.12442/11380oai:bonga.unisimon.edu.co:20.500.12442/113802024-08-14 21:53:44.63http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internacionalopen.accesshttps://bonga.unisimon.edu.coRepositorio Digital Universidad Simón Bolívarrepositorio.digital@unisimon.edu.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 |